1. In 2014, he was awarded the Second Prize of National Scientific and Technological Progress: "Establishment and Application of New Prevention and Treatment Technology for Primary Open-Angle Glaucoma"
Primary open-angle glaucoma (commonly known as "open glaucoma") is the world's first irreversible blinding eye disease. The blindness rate of open-angle glaucoma in China is 15%~30%, which is much higher than the average level of 8% in developed countries. In response to the above problems, the study took the key technology and equipment for screening and monitoring of open glaucoma as a breakthrough, and was the first to create and implement a screening model for open glaucoma based on digitization and network technology in China: two large-scale streaming surveys were conducted to identify the risk factors and populations of open glaucoma in China. Through the study of the anatomical parameters of the fundus optic disc and optic nerve fiber layer, the screening technology and standards for cyanosis based on digital fundus photography were established. By utilizing remote network technology and effectively integrating three levels of medical resources, it has realized for the first time a paradigm shift from treatment to community-based prevention and control of Keloids, increasing the detection rate of Keloids in the population from 10% to 95%.
2. In 2013, we were awarded the Second Prize of National Scientific and Technological Progress: "The Establishment and Application of the Pathogenesis and Prevention System of Primary Closed-Angle Glaucoma"
Primary closed-angle glaucoma (referred to as closed glaucoma) is the most common irreversible blindness in China and even in the Asian region, with 10.1 million people suffering from closed glaucoma in China. Currently, 10.1 million people in China suffer from occlusion. This study started from answering the scientific question of the pathogenesis of AMD, and established a new AMD prevention and treatment technology system by solving the key technologies and equipments as a breakthrough. Based on the mechanism theory and classification system, as well as new screening and diagnostic techniques, a model for diagnosis and treatment of AMD has been established that is suitable for grassroots and large hospitals respectively, which reduces the rate of early AMD intervention by 40%. We have designed a rescue treatment pathway for acute episodes of amaurosis and promoted it in China, which has reduced the blindness rate of acute amaurosis by 70%. Evidence-based evaluation of traditional surgical indications for amaurosis, and establishment of a sequential treatment model of drug, laser, and surgery, which reduced the surgical rate from 80% to 14%. The project has been popularized and applied in 22 provinces and cities, covering 130 million people and benefiting about 1 million patients with amaurosis, reducing the blindness rate from 37.5%-75% to 4%-11.6%. The project has accomplished the leap from technology tracking to technology leading in the prevention and treatment of blindness in China.
3. 2012 First Prize of Chinese Medical Science and Technology Award: "Creation and application of primary open-angle glaucoma mechanism and new diagnosis and treatment model"
4. 2011 First Prize of Chinese Medical Science and Technology Award: "Primary closed-angle glaucoma prevention and treatment technology and popularization"
5. 2009 First Prize of Ministry of Education's Natural Science Prize: "The cytoskeleton and extracellular matrix of the atrial aqueous humor flow channel. Research on the Role Mechanism of Cytoskeleton and Extracellular Matrix in the Regulation of Intraocular Pressure (IOP)
6. First Prize of the Natural Science Award of Chinese Universities in 2001 (Natural Science Award of the Ministry of Education): "A Series of Studies on the Pathogenesis and Classification of Primary Closed-Angle Glaucoma in China"
7. In 2015, he was awarded the honorary title of "Advanced Worker of the Nation", and selected as "Outstanding Worker of the Beijing High-level Innovation and Entrepreneurship Talent Program". In 2015, he was honored as a National Advanced Worker and selected as a "Outstanding Talent of Beijing High-level Innovation and Entrepreneurship Talent Program"
8. In 2014, he was honored as a National Outstanding Scientific and Technological Worker, won the Clinician Award of Zhou Guangzhao Foundation, was elected as a Fellow of the International Academy of Ophthalmology, and was ranked as one of the 100 most influential ophthalmologists in the world by Ophthalmologist magazine. In 2013, Prof. Wang was selected as one of the "Beijing Scholars" and received the Golden Apple Award of Chinese Ophthalmology from the Sino-American Society of Ophthalmology
Professor Wang Ningli*** has published 383 academic papers, of which 151 have been indexed in the SCI; a number of articles have been published in the journals Nature, Genetics, Progress, and the Journal of Ophthalmology, as well as the Journal of the American Academy of Ophthalmology. Prof. Wang has published 383 academic papers, including 151 SCI-indexed papers, many of which have been published in Nature, Genetics, Progress in Retinal and Eye Research, Ophthalmology, and other high-impact journals. He has received 6 national patents, edited 9 books, and won 7 awards at the provincial and ministerial levels, including the Second Prize for National Scientific and Technological Progress and the Chinese Medical Science and Technology Award.
In view of the above research results, Wang Ningli has been recognized as a young and middle-aged expert with outstanding contributions by the Ministry of Health, a recipient of the State Council Special Allowance, a recipient of the Outstanding Achievement Award in Chinese Ophthalmology, the Outstanding Scientific Achievement Award of the Asia-Pacific Association of Ophthalmology, a Senior Clinician Scientist by the WGA, and a leading ophthalmologist in the Beijing Health System. 2011 saw the award of the Arthur Lim Award of the Asia-Pacific Association of Ophthalmology. In 2011, he received the Arthur Lim Award from the Asia-Pacific Association of Ophthalmology (APAO), which recognizes Wang as an outstanding leader and educator in ophthalmology in China and Asia-Pacific who has made outstanding contributions to ophthalmology in the areas of clinical practice, teaching, and research, and in 2012, he was honored with the 4th Special Contribution Award for Overseas Educated Personnel in Beijing for Innovation and Entrepreneurship.